Building Partnerships...




Proximagen is well suited to be the partner of choice in the area of CNS, having the capabilities and financial strength of a much larger company. We can offer potential partners, or their investors, the resources needed to support a drug candidate as it advances from the laboratory and through the clinic.


Visit our partnering section for more information...




Our Pipeline...




Our passion for advancing innovation is evident in the breadth and depth of our pipeline.

Visit our pipeline...


Please find links to PDF's of our Press Releases below..




2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004

DATE TITLE SOURCE
01/02/10 Proximagen on acquisition trail with 55.5m war chest IB Times
15/01/10 The welcome shrinkage of junior market's long tail Financial Times
04/01/10 Proximagen buys Minster for £4.3m Financial Times
02/02/09 New non-executive chairman for Proximagen The Independent
28/07/08 Boost for biotechs by Proxi The Independent
24/07/08 Proximagen seals a deal Shares Magazine
24/07/08 Proximagen Signs Licensing Agreement with Upsher-Smith BioCentury
16/07/08 Proximagen Signs Licensing Agreement with Upsher-Smith BioWorld International (AHC Media)
02/01/08 Share tips 2008 The Independent
23/06/07 Extras, extras! New Scientist
21/06/07 The Investment Column The Independent
14/06/07 Proximagen Shares Magazine Article Shares Magazine
07/03/07 Proximagen reveals promising alternative to L-DOPA for Parkinson's disease Scrip World Pharmaceutical News
27/07/05 Proximagen interim results Financial Times
29/03/05 CNBC Power Lunch Interview CNBC
29/03/05 University floats spinout Daily Express
15/03/05 Proximagen to list on AiM Financial Times
03/12/04 Entrepreneurs Welcome Science Spotlight The Guardian
15/08/04 Neuroscience Research Company Launched The Messenger
18/03/04 Stock Market News: Proximagen is a spinout from Kings Market Release